The Global Diabetes Drug Intelligence Center 2012-2023 report is now available on, according to Business Wire.

The report covers data for 25 major countries, offering 13 years of comparable data and a five-year forecast, including market value, volume sales, price, and trends.

The intelligence center report will enhance your understanding of the diabetes drugs industry. It offers key insights into economic factors that influence drug usage for Type 1 and Type 2 diabetes, and obesity.

Key players involved in the global diabetes drug market include Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen Pharmaceuticals, Merck and Co., Novartis, Novo Nordisk, Pfizer, Sanofi, and Takeda.

In addition, the report includes diabetic population levels, prevalence, incidence, Type-1 and Type-2 diabetic population levels, and per capita expenditure.

Insulin categories include insulin, long-acting Insulin, bolus (fast-acting) insulin, pre-mixed Insulin or combination Insulin, traditional human insulin, traditional human insulin biosimilars, insulin glargine biosimilars, non-insulin Injectable, and amylin analog.

Oral hypoglycemic agents (OHAs) include dopamine -D2 receptor agonist, meglitinide, alpha-glucosidase inhibitors, SGLT2 inhibitors, biguanides, sulfonylureas, DPP-4 inhibitors, and other combination drugs.

Experts believe that the market will reach $94 billion by 2023 at a CAGR of 5.65%, with the insulin segment holding the highest market share, which is mostly dominated by leading drug companies, such as Sanofi, Novo Nordisk, and Eli Lilly.

Globally, the prevalence of diabetes has increased over the last decade. There are several reports and surveys documenting a tremendous increase in the diabetic population due to changing lifestyles and habits. The prevalence of Type 2 diabetes, in particular, has increased significantly due to these factors.

Surprisingly, most people go undiagnosed. It is estimated that out of the total 415 million people with diabetes worldwide, 46% go undiagnosed.

Injectable insulin does well but experts believe that oral insulin drugs could boost the market.

Indian pharmaceutical company Biocon is developing Tregopil, a first-in-class oral insulin molecule, for the treatment of both Type 1 and Type 2 diabetes. The fast-acting oral insulin tablet may improve post-prandial blood glucose level with reduced side effects and greater compliance, thereby holding the promise to transform Type 1 diabetes management.

Similarly, Jerusalem-based Oramed Pharmaceuticals is developing oral drug delivery systems. It is working to bring the first oral insulin delivery product that can provide a more convenient, effective, and safer method for delivering insulin. The article was published in Business Wire.